BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34724198)

  • 1. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
    Lu E; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Zavoshi S; Li S; Zhang L; Wilde BR; Christofk HR; Boutros PC; Shuch B
    Cancer; 2022 Feb; 128(4):675-684. PubMed ID: 34724198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
    Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
    Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma.
    Zavoshi S; Lu E; Boutros PC; Zhang L; Harari A; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Wilde B; Christofk H; Shuch B
    Urology; 2023 Jun; 176():106-114. PubMed ID: 36773955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
    Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
    J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
    Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
    Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Detection of Germline Mutation of Fumarate Hydratase in Women With Uterine Smooth Muscle Tumors Using Pathology-based Screening to Trigger Genetic Counseling for Hereditary Leiomyomatosis Renal Cell Carcinoma Syndrome: A 5-Year Single Institutional Experience.
    Rabban JT; Chan E; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 May; 43(5):639-655. PubMed ID: 30741757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
    Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
    Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
    Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
    Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
    Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
    Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome.
    Breen KE; Carlo MI; Kemel Y; Maio A; Chen YB; Zhang L; Ceyhan-Birsoy O; Mandelker D
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1293. PubMed ID: 32463173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma.
    Chami A; de Souza Zózimo TR; Alves TM; Matosinho CGR; Santos C; Simões MM; Cabral WLR; de Paula Ricardo BF; da Silva Filho AL; Carvalho MRS; da Conceição Braga L
    Fam Cancer; 2023 Oct; 22(4):481-486. PubMed ID: 37316640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
    Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
    Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Bhola PT; Gilpin C; Smith A; Graham GE
    Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation.
    da Cunha IW; da Costa WH; Morini MA; Bezerra SM; Carraro DM; Torrezan GT; Formiga MNC; Guimaraes GC; Zequi SC; Soares FA
    Virchows Arch; 2018 Dec; 473(6):775-779. PubMed ID: 30171332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
    Garg K; Rabban J
    Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.